Standout Papers

Comparison of ixekizumab with etanercept or placebo in moderate-to... 2010 2026 2015 2020 634
  1. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials (2015)
    C.E.M. Griffiths, Kristian Reich et al. The Lancet
  2. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis (2010)
    C.E.M. Griffiths, Bruce Strober et al. New England Journal of Medicine
  3. Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions (2010)
    Batya B. Davidovici, Naveed Sattar et al. Journal of Investigative Dermatology

Immediate Impact

1 by Nobel laureates 13 from Science/Nature 99 standout
Sub-graph 1 of 20

Citing Papers

Active biointegrated living electronics for managing inflammation
2024 StandoutScience
TH17 cell heterogeneity and its role in tissue inflammation
2023 Standout
11 intermediate papers

Works of Peter van de Kerkhof being referenced

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
2015 Standout
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
2010 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Peter van de Kerkhof 2196 1504 145 462 47 3.0k
Yihua Gu 2010 2112 381 531 56 3.6k
Jennifer Clay Cather 1788 1244 81 408 69 2.5k
Henry W. Lim 2249 1463 189 360 31 2.9k
Sandra Philipp 2518 1536 150 452 74 3.4k
Caitriona Ryan 2122 1296 130 493 54 3.0k
J.‐P. Ortonne 1974 1479 253 545 69 3.3k
April W. Armstrong 2296 1370 127 606 74 3.2k
Jerry Bagel 2014 1436 235 453 115 2.6k
T Fredriksson 1869 1204 170 592 54 2.9k
Michel Le Maître 1882 1125 123 687 41 2.5k

All Works

Loading papers...

Rankless by CCL
2026